Through the last posting on the daily approval list on September 16, OGD has reported only 16 full approval actions and one tentative approval action. If this rate keeps up through the rest of the month, we are likely to see the fewest number of monthly approval actions since the beginning of the GDUFA program. […]
It’s another month of full stats in the books, but not much to cheer about. Let’s have a look at some of the highlights (or lowlights, if you will) of the month’s statistics. OGD Refused-to-Receive (RTR) 4 ANDAs in July and all four were for standard ANDAs. The average RTRs per month through the first […]
Today, the FDA issued a guidance document titled Development of Abbreviated New Drug Applications During the COVID-19 Pandemic – Questions and Answers (here). This guidance responds to questions that have been asked by sponsors since the pandemic began, covers a multitude of issues, and outlines some areas of relief for applicants. Remember that the answers […]
The Federal Register announced the BsUFA fees for FY 2022 today (here) and, for the second year in a row, the fees have decreased or, in the case of applications, stayed the same. Fee Category Rates for FY 2021 Rates for FY 2022 Percent Change Initial BPD $102,494 $57,184 -44.3 Annual BPD $102,494 $57,184 -44.3 […]
The FDA issued its final guidance on Field Alert Reports (FARs) today (here). This guidance finalizes the draft guidance of the same title issued on July 19, 2018. FARs have been the subject of much misunderstanding and interpretation regarding when, what, how, and where reports should be sent. I can’t tell you how many times […]
The FDA announced the Generic Animal Drug User Fee Rates for FY 2022 in today’s Federal Register here. This will be a first in an avalanche of announcements of new User Fee rates for the coming FY. The rates for Generic Animal Drugs for FY 2022 are provided in the table below: Fee Category […]
With the news that domestic inspections are back on track the question comes with what is the backlog and how long will it take to slug through the outstanding inspections work? Question number 2 is then what do we anticipate seeing from these new domestic inspections? With it being over a year+ (March 2020) since […]
If you have been in the generic industry for, as they say, a minute, you know that one of the major and years old problem generic applicants have faced is being able to obtain samples of the reference listed drug (RLD) product to use in required bioequivalence (BE) testing to support approval of an abbreviated […]
As of today, July 19, 2021, FDA has posted its approvals up to and including July 15th, and the scorecard thru the top of the 4th inning is reported at 27 full approval actions and 2 tentative approval actions. If the current rate of approval actions holds for the month, we should see total approval […]
Dr. Janet Woodcock, the Acting FDA commissioner, is a long-time career executive having begun her tenure in 1986. Full disclosure, I worked with or for her when I was at the Office of Generic Drugs from 1985 through December 1995 in various capacities. She has been serving as Acting Commissioner since her appointment for over […]
